AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients

RecruitingNAAges 19 Years - 80 YearsAllYonsei University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement. However, concerns remain about the safety of long-term clopidogrel monotherapy in high-risk patients with HPR (high platelet reactivity) who do not respond adequately to clopidogrel. This study aims to evaluate the effectiveness of a patient-tailored antiplatelet therapy strategy that considers platelet aggregation in high-risk patients with DES placement beyond 12 months after stenting.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patients \> 18 years old 2. Patients who previously underwent percutaneous coronary intervention with drug-eluting stent implantation 12 months (ยฑ 3 months) ago. 3. At least one high risk characteristics of ischemic events High risk patients 1. Acute coronary syndrome 2. Previous history of cerebrovascular accidents 3. Previous history of peripheral artery intervention 4. Heart failure 5. Diabetes mellitus requiring medication 6. Chronic kidney disease (regardless of requirement of renal replacement therapy) High risk lesions 1. Left main disease 2. Multivessel disease, 2- or 3- vessels 3. Bifurcation lesions requiring 2 or more stents 4. Chronic total occlusion 5. In-stent restenosis 6. Graft lesions 7. Diffuse long lesion requiring stent(s) with total stent length โ‰ฅ28 mm 8. Lesion at small sized vessel requiring stent(s) with stent diameter โ‰ค2.5 mm 9. Calcified lesions requiring atherectomy Exclusion Criteria: 1. Patients \> 80 years old 2. Pregnant women or women with potential childbearing 3. Life expectancy \< 1 year 4. Refusal or inability to understand of informed consent 5. Patients eligible to long-term anticoagulation therapy 6. Patients with major bleeding events in previous 3 months before randomization
๐Ÿ’Š

What it tests

  • Clopidogrel monotherapy
  • Tailored anti-platelet therapy
๐Ÿ“

Where

1 site
Severance Hospital
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy